MBIO News and Press, Mustang Bio Inc. From 10/17/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

Horizon Technology Finance Provides Third Quarter 2020 Portfolio Update - Originates $16.0 Million of New Loans - - Positive Liquidity Events of $45 Million Demonstrate Earnings Strength of Portfolio - PR Newswire FARMINGTON, Conn., Oct. 7, 2020 FARMINGTON,...

Mustang Bio (MBIO) inks an agreement with SIRION Biotech GmbH securing rights to the latter's LentiBOOST technology for the development of MB-207, a gene therapy for X-linked severe combined immunodeficiency, also known as "bubble boy disease."The company says LentiBOOST enables a robust and ...

WORCESTER, Mass. and MARTINSRIED, Germany, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO) and SIRION Biotech GmbH (“SIRION”) today announced a licensing agreement under which Mustang has acquired rights to SIRION’s LentiBOOS...

WORCESTER, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

The first participant has been dosed in a 126-subject Phase 1/2 clinical trial evaluating Mustang Bio's (MBIO) CAR T therapy MB-102 in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia and high-risk myelodysplastic syndromes.The fir...

WORCESTER, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

Are These On Your List Of Penny Stocks To Buy Right Now? No matter if you’re looking for penny stocks to buy or invest in, you’ve got the run of the mill. There are thousands of stocks under $5 that captivate attention on a daily basis. Herein lies the dilemma of sorts...

WORCESTER, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...